| Charla Faye Holst, | |
|
409 W Locust St, Aurora, MO 65605-1422 | |
| (417) 678-3373 | |
| (417) 678-4043 |
| Full Name | Charla Faye Holst |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 409 W Locust St, Aurora, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841327954 | NPI | - | NPPES |
| 476914106 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 1999134935 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Charla Faye Holst, 409 W Locust St, Aurora, MO 65605-1422 Ph: (417) 678-3373 | Charla Faye Holst, 409 W Locust St, Aurora, MO 65605-1422 Ph: (417) 678-3373 |
News Archive
Bariatric surgery for obese patients is not cost-saving relative to medical care, shows a 6-year follow-up study in JAMA Surgery.
A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients.
Aradigm Corporation today announced that it has entered into a Stock Purchase Agreement providing for the issuance by the Company of 26 million shares of the Company's common stock to Novo Nordisk A/S in a private placement as consideration for the termination of a promissory note in favor of Novo Nordisk under which approximately $9.1 million is currently outstanding, representing an effective price per share of $0.3505.
Repros Therapeutics Inc. today announced it has commenced randomization of subjects into its Phase II Androxal® study in the treatment of type 2 diabetes (T2DM) in men with low testosterone. Low testosterone and T2DM are co-morbid conditions in a significant number of men. The study is being conducted at nine sites across the US including both academic and private practices and will enroll up to 150 patients.
› Verified 8 days ago